Skip to main content

Find Clinical Trials

Home
Conditions
Triple Negative Breast Cancer (TNBC)

Clinical trial condition

Triple Negative Breast Cancer (TNBC)

Explore clinical trials studying Triple Negative Breast Cancer (TNBC). Study availability and eligibility vary by location and protocol.

54 public trials 28 recruiting studies

Refine in advanced search Browse all conditions

Triple Negative Breast Cancer (TNBC) trial results

Not yet recruiting

An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBC

NCT07760844

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +6 more
Locations: Not specified

View Trial Details

Not yet recruiting

An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC

NCT07669610

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +6 more
Locations: Not specified

View Trial Details

Not yet recruiting

Circulating Tumor DNA Dynamics to Optimize Neoadjuvant Therapy in HER2-Positive and Triple-Negative Breast Cancer

NCT07662252

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +7 more
Locations: Not specified

View Trial Details

Not yet recruiting

Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)

NCT07527819

Conditions: Adnexal Diseases, Breast Diseases, Breast Neoplasms, +18 more
Locations: Chris O'Brien Lifehouse Camperdown, New South Wales, Australia

Mater Hospital Sydney Sydney, New South Wales, Australia

Lyell McEwin Hospital Adelaide, South Australia, Australia

Icon Cancer Centre Hobart, Tasmania, Australia

View Trial Details

Not yet recruiting

Adjuvant Intensification for LAR

NCT07407517

Conditions: Breast Cancer Females, Breast Diseases, Breast Neoplasms, +6 more
Locations: Not specified

View Trial Details

Not yet recruiting

Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis

NCT07246759

Conditions: Adenocarcinoma, Breast Diseases, Breast Neoplasms, +41 more
Locations: Heidelberg University Hospital Heidelberg, Germany

Intituto Europeo di Oncologia SRL Milan, Italy

Virgen Macarena University Hospital - Servicio Andaluz de Salud Seville, Spain

View Trial Details

Not yet recruiting

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

NCT07187674

Conditions: Breast Diseases, Breast Neoplasms, Neoplasms, +5 more
Locations: Not specified

View Trial Details

Not yet recruiting

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

NCT07161791

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +6 more
Locations: Not specified

View Trial Details

Not yet recruiting

Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer

NCT07153965

Conditions: Breast Diseases, Breast Neoplasms, Neoplasms, +6 more
Locations: Tianjin Medical University Cancer Institute and Hospital Tianjin, Tianjin Municipality, China

View Trial Details

Not yet recruiting

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

NCT06731153

Conditions: Breast Diseases, Breast Neoplasms, Metastatic Breast Cancer, +6 more
Locations: Breast cancer institute of Fudan University Cancer Hospital Shanghai, Shanghai Municipality, China

View Trial Details